TScan Therapeutics (NASDAQ:TCRX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $11.00 target price on the stock.

Several other equities analysts have also recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, TScan Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX opened at $5.42 on Tuesday. The company has a 50 day simple moving average of $5.35 and a two-hundred day simple moving average of $6.53. The stock has a market cap of $287.12 million, a price-to-earnings ratio of -5.16 and a beta of 0.79. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. TScan Therapeutics has a 12 month low of $3.73 and a 12 month high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. The company had revenue of $0.54 million during the quarter, compared to the consensus estimate of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. As a group, analysts predict that TScan Therapeutics will post -1.17 earnings per share for the current year.

Insider Activity at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were bought at an average cost of $5.69 per share, with a total value of $28,450.00. Following the completion of the acquisition, the director now owns 35,000 shares in the company, valued at approximately $199,150. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Barbara Klencke acquired 5,000 shares of TScan Therapeutics stock in a transaction on Friday, August 23rd. The stock was bought at an average cost of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the transaction, the director now owns 35,000 shares of the company’s stock, valued at approximately $199,150. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the sale, the insider now owns 4,716 shares in the company, valued at approximately $27,258.48. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders acquired a total of 15,000 shares of company stock worth $82,550 in the last 90 days. Corporate insiders own 2.76% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new stake in shares of TScan Therapeutics in the second quarter worth approximately $70,000. The Manufacturers Life Insurance Company purchased a new position in TScan Therapeutics in the 2nd quarter valued at $90,000. SG Americas Securities LLC acquired a new stake in TScan Therapeutics during the 3rd quarter worth $78,000. Cornercap Investment Counsel Inc. purchased a new stake in shares of TScan Therapeutics during the second quarter worth $134,000. Finally, Rhumbline Advisers acquired a new stake in shares of TScan Therapeutics in the second quarter valued at about $274,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.